Brief: Consun Pharmaceutical Group Updates On Progress In Application For New Medicine Registration
March 15 (Reuters) - Consun Pharmaceutical Group Ltd
1681.HK :
* UNITS GRANTED "CLINICAL TRIAL APPROVAL" BY CHINA FDA FOR
"ASTRAGALI POWDER PELLET", A PIPELINE MEDICINE
Source text for Eikon: ID:nHKS950M9F
Further company coverage: 1681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Consun Pharmaceutical
See all newsChina's Consun Pharmaceutical H1 revenue rises on sales network expansion
Brief: Consun Pharmaceutical Says Unit To Invest RMB191.4 Mln In Shanghai Huamao Pharmaceutical
Brief: Consun Pharmaceutical Group Announces Share Repurchase Program Up To HKD200 Million
Brief: Consun Pharmaceutical Logs FY Revenue RMB 3,420 Mln
Brief: Consun Pharmaceutical Says Executive Director Zhu Quan Redesignated As Non-Executive Director